ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1097

Tankyrase Regulates Osteoclastogenesis Via SH3BP2

Shunichi Fujita, Tomoyuki Mukai, Takafumi Mito, Shoko Kodama, Akiko Nagasu, Hiroyasu Hirano and Yoshitaka Morita, Department of Rheumatology, Kawasaki Medical School, Kurashiki, Okayama, Japan

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: bone biology, osteoclastogenesis and osteoclasts

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 14, 2016

Session Title: Biology and Pathology of Bone and Joint - Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Tankyrase is a poly (ADP-ribose) polymerase that leads to ubiquitination and degradation of target proteins. Axin, a regulatory protein of Wnt/β-catenin signaling, is one of the target proteins of tankyrase, therefore tankyrase inhibitors function as a Wnt/β-catenin inhibitor. Tankyrase has recently been reported to degrade an adaptor protein SH3BP2 (SH3 domain-binding protein 2). We have previously reported that SH3BP2 gain-of-function mutation in murine bone marrow-derived macrophages enhances RANKL-induced osteoclastogenesis. Though the interaction between tankyrase and SH3BP2 has been reported, it is not fully elucidated whether tankyrase is involved in osteoclastogenesis. In this study, we investigated the role of tankyrase in bone metabolism.

Methods: Primary murine bone marrow-derived macrophages and murine preosteoclastic RAW264.7 cells were treated with RANKL in the presence of tankyrase inhibitors (IWR1 or XAV-939) and Wnt inhibitors (ICG001 or IWP2). Osteoclasts were visualized by a tartrate-resistant acid phosphatase (TRAP) staining, and TRAP-positive multinucleated cells (TRAP+ MNCs) were counted as osteoclasts. Expression levels of osteoclast-associated genes (Cathepsine K, Oscar, Acp5 and Dc-stamp) were measured by quantitative PCR analysis. Osteoclastic function was assessed by resorption assay. To determine the intracellular mechanisms, protein expression patterns of SH3BP2, NFATc1, and Syk were examined by western blotting.

Results:  Both IWR1 and XAV-939 enhanced RANKL-induced TRAP+ MNCs formation, osteoclast-associated genes expression, and mineral resorbing activity. SH3BP2 protein levels were elevated in cells treated with tankyrase inhibitors but not with Wnt inhibitors. Tankyrase inhibitors significantly augmented nuclear localization of NFATc1 and phosphorylation of Syk in response to RANKL. Finally, FK506, an NFATc1 inhibitor, fully abolished the promoting effect of tankyrase inhibitors on osteoclast formation.

Conclusion:  These findings suggest that the inhibition of tankyrase enhances osteoclastogenesis through activating Syk and NFATc1 via elevated SH3BP2 expression. Our findings highlight the undetermined effect of tankyrase inhibition in addition to its suppressive effect on Wnt/β-catenin signaling. Modulating tankyrase activity could be a novel therapeutic option of bone destructive diseases including osteoporosis and rheumatoid arthritis.


Disclosure: S. Fujita, None; T. Mukai, Takeda Pharmaceutical Co., Ltd., 2,Pfizer Japan Inc., 2,Mitsubishi Tanabe Pharma Co., 2,Chugai Pharmaceutical Co., Ltd., 2,Eisai Co., Ltd., 2,AbbVie GK, 2,TEIJIN Pharma Ltd., 2,Astellas Pharma Inc., 2,Japan Blood Products Organization, 2,Shionogi & Co., Ltd, 2,Actelion Pharmaceuticals Japan Ltd., 2,Bristol-Myers Squibb, 2,Eli Lilly Japan K.K., 2,DAIICHI SANKYO Co., Ltd., 2,Taisho Toyama Pharmaceutical Co., Ltd., 2,Santen Pharmaceutical Co., Ltd., 2; T. Mito, None; S. Kodama, None; A. Nagasu, None; H. Hirano, None; Y. Morita, Takeda Pharmaceutical Co., Ltd., 2,Pfizer Japan Inc., 2,Mitsubishi Tanabe Pharma Co., 2,Chugai Pharmaceutical Co., Ltd., 2,Eisai Co., Ltd., 2,AbbVie GK, 2,TEIJIN Pharma Ltd., 2,Astellas Pharma Inc., 2,Japan Blood Products Organization, 2,Shionogi & Co., Ltd, 2,Actelion Pharmaceuticals Japan Ltd., 2,Bristol-Myers Squibb, 2,Eli Lilly Japan K.K., 2,DAIICHI SANKYO Co., Ltd., 2,Taisho Toyama Pharmaceutical Co., Ltd., 2,Santen Pharmaceutical Co., Ltd., 2.

To cite this abstract in AMA style:

Fujita S, Mukai T, Mito T, Kodama S, Nagasu A, Hirano H, Morita Y. Tankyrase Regulates Osteoclastogenesis Via SH3BP2 [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/tankyrase-regulates-osteoclastogenesis-via-sh3bp2/. Accessed February 2, 2023.
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/tankyrase-regulates-osteoclastogenesis-via-sh3bp2/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences